arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

REGENERON PHARMACEUTICALS, INC.

REGN
$771.96 ▲ +3.30 (+0.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
84
Health
Excellent
Bullish
auto_awesome

Analytical Summary

REGENERON PHARMACEUTICALS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $80.7B
Dividend Yield
Revenue Growth 1.0%
Op. Margin 24.9%
ROIC 9.3%
FCF / Share $47.60
Trailing P/E 17.9x
Price / Book 2.6x
FCF Yield 6.2%
Debt / Equity 0.06
info Valuation on last close. End-of-day price, Aug 6, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$14.34B
↑ +1.0%
Net Income Profit after all expenses
$4.50B
↑ +2.1%
Operating Margin Operating profit as % of sales
24.9%
↓ -11.2% 82th
FCF / Share Free cash flow per share
$47.60
↑ +16.2%
Long-Term Debt Long-term obligations
$1.99B
— +0.1%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
90
Returns
79
Financial Health
90
Cash Quality
70

Dividend History

Dividend / share · sourced from SEC filings
$0.94 Latest / share
+0.0% YoY

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 72 quarters